AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE
ISSN: 2996-5101 (online) | ResearchBib (IF) = 10.81 IMPACT FACTOR
Volume-4| Issue-5| 2026 Published: |30-05-2025|

THE ROLE OF THE CLINICAL PHARMACIST IN OPTIMIZING DRUG THERAPY

https://doi.org/10.5281/zenodo.20374042

Kholisova Dinarakhon Ravshan qizi

Abstract

This article provides a comprehensive analysis of the clinical pharmacist's role in the modern healthcare system, their responsibilities in the drug therapy optimization process, and the positive impact they have on patient health outcomes. Clinical pharmacy is a contemporary discipline that has emerged at the intersection of pharmaceutical science and clinical medicine, ensuring the safe, effective, and economically rational use of medications in collaboration with physicians, nurses, and other healthcare professionals. It has been scientifically demonstrated that the active involvement of clinical pharmacists in global healthcare practice reduces the incidence of adverse drug reactions (ADRs) by 45–66%, shortens hospital stays, and significantly decreases overall treatment costs. The article discusses the problem of polypharmacy, drug-drug interactions, medication adherence, and the specific mechanisms through which clinical pharmacists address these challenges. In conclusion, the article emphasizes that developing the field of clinical pharmacy and implementing it broadly into practice is one of the priority tasks of the modern healthcare system.

Keywords

clinical pharmacist, drug therapy, polypharmacy, ADR (adverse drug reaction), drug-drug interaction, adherence, pharmacotherapeutic monitoring, drug safety, multidisciplinary team, pharmacoeconomics.

Introduction

Throughout the history of pharmaceutical science, the pharmacist (provisor) has traditionally been regarded as a specialist primarily engaged in the preparation and dispensing of medications. However, beginning in the second half of the 20th century, the growing complexity of medical practice, the expansion of multi-morbid (comorbid) disease presentations, and the rapid increase in the number of new pharmaceutical products on the market created the foundation for a qualitatively new stage in pharmacy the field of clinical pharmacy. In the 1960s, at the University of California, San Francisco campus, the principles of clinical

pharmacy began to take formal shape, and since that time the discipline has been developing rapidly.

Today, on a global scale particularly in the United States, the United Kingdom, Canada, Australia, and Scandinavian countries clinical pharmacists are actively working in hospitals, outpatient clinics, intensive care units, oncology centers, and home care services. The World Health Organization (WHO) and the International Pharmaceutical Federation (FIP) have also recognized clinical pharmacy as an essential component of patient-centered care and are recommending its integration into national healthcare policies. Although this field is still in a developmental stage for Uzbekistan and Central Asian countries, interest in and demand for clinical pharmacy has been growing year by year within the framework of medical education reforms.

Main body

A clinical pharmacist is not merely a medication dispenser, but rather a specialist who monitors and optimizes a patient's pharmacotherapy from start to finish. Their responsibilities are manifested in the following areas:

First, assessment and optimization of drug therapy the clinical pharmacist analyzes the patient's medication regimen, identifies inappropriately prescribed drugs, duplications, or medications with harmful interactions, and provides relevant recommendations to the physician.

Second, ensuring drug safety the clinical pharmacist plays a central role in the system of monitoring, detecting, and reporting adverse drug reactions (ADRs).

Third, patient education the clinical pharmacist provides patients with guidance on correct medication intake, storage, completing the full course of treatment, and timely recognition of side effects.

Fourth, participation in a multidisciplinary team the clinical pharmacist participates in pharmacotherapeutic decision-making alongside physicians, nurses, dietitians, and other specialists.

The Problem of Polypharmacy and the Significance of the Clinical Pharmacist

Polypharmacy the concurrent use of five or more medications has become one of the most pressing issues in modern medicine. This condition is particularly widespread among patients over the age of 65: in the United States, more than 40% of elderly patients have been recorded as taking five or more medications simultaneously (Masnoon et al., 2017). Polypharmacy leads to a number of serious problems, including drug-drug interactions (DDIs), overdose, duplication of pharmacologically equivalent agents, and ultimately non-adherence to the medication regimen. The clinical pharmacist addresses these problems in a comprehensive manner by compiling the patient's complete medication list

(medication reconciliation) and evaluating each drug in terms of its clinical appropriateness. Research indicates that medication audits conducted under the supervision of a clinical pharmacist can reduce polypharmacy-related hospital admissions by up to 30% (Johansson et al., 2016).

Drug-Drug Interactions and ADR Monitoring

Drug-drug interactions (DDIs) represent a significant risk factor in modern clinical practice. In combination with other factors, these situations can lead to potentially dangerous clinical outcomes, including toxic effects, loss of therapeutic efficacy, or disruption of dosing for agents such as anticoagulants. Warfarin, digoxin, lithium, and a number of antiepileptic drugs fall into the high-risk category for clinically significant drug interactions. Using specialized knowledge and electronic decision-support systems (such as Micromedex, Lexicomp, and Clinical Pharmacology), the clinical pharmacist carefully reviews the patient's medication list to identify potentially hazardous combinations at an early stage. According to a study conducted by Cheung et al. (2014), ADR surveillance programs led by clinical pharmacists reduced the incidence of adverse drug reactions in hospital wards by up to 66%.

Chronic Disease Management and Drug Therapy

In chronic conditions such as diabetes mellitus, arterial hypertension, heart failure, and bronchial asthma, drug therapy is complex, multi-component, and long-term in nature. In these diseases, full patient adherence to the treatment regimen is one of the primary determinants of therapeutic efficacy. According to WHO data, approximately 50% of patients with chronic diseases do not fully comply with their prescribed medication regimen, which leads to disease exacerbation and frequent hospitalization. The clinical pharmacist assesses the patient's knowledge, motivation, and ability regarding medication intake, implements individualized educational programs for each patient, and improves adherence through dosing schedules and reminders. Meta-analyses conducted in pharmacist-managed chronic disease clinics have documented significant improvements in achieving target values for blood pressure, HbA1c levels, and LDL cholesterol (Santschi et al., 2014).

The Pharmacoeconomic Significance of the Clinical Pharmacist

In the context of limited healthcare resources, the role of the clinical pharmacist as a generator of economic value is of particular importance. A growing body of research demonstrates that every dollar invested in clinical pharmacy services yields savings of between $3 and $12. These savings are realized through: discontinuation or substitution of inappropriately prescribed medications with more cost-effective alternatives; reduction in hospitalizations caused by drug-

related problems (DRPs); appropriate introduction of generic medications; and shortening of the treatment course through optimized drug therapy. According to the results of a clinical study conducted by Spinewine et al. (2007), medication optimization carried out with the involvement of a clinical pharmacist reduced inpatient treatment costs by an average of 13%. This issue is particularly significant for Uzbekistan, as a large portion of the country's drug expenditures falls directly on patients.

Conclusion

Clinical pharmacy is an advanced discipline built on a patient-centered approach that elevates the modern healthcare system to a qualitatively new level. The evidence presented above demonstrates that the active involvement of the clinical pharmacist in a multidisciplinary team simultaneously improves the safety, efficacy, and economic rationality of drug therapy. In the context of growing challenges such as polypharmacy, ADRs, drug-drug interactions, and low adherence, the clinical pharmacist plays an indispensable and necessary role.

To develop this field in Uzbekistan, the following measures should be implemented: broad integration of clinical pharmacy modules into pharmaceutical education; legislative consolidation of the positions and competencies of hospital pharmacists; support for continuing professional development of clinical pharmacists; and integration of their activities with healthcare information systems. Without these steps, systemic problems economic losses, preventable morbidity, and mortality will persist. Making clinical pharmacy a priority direction of national healthcare policy is both a pressing necessity and a professional responsibility of our time.

REFERENCES:

1. World Health Organization. (2019). Medication Without Harm: WHO Global Patient Safety Challenge. Geneva: WHO Press.
2. Masnoon, N., Shakib, S., Kalisch-Ellett, L., & Caughey, G. E. (2017). What is polypharmacy? A systematic review of definitions. BMC Geriatrics, 17(1), 230. https://doi.org/10.1186/s12877-017-0621-2
3. Cheung, K. C., Bouvy, M. L., & De Smet, P. A. G. M. (2009). Medication errors: the importance of safe dispensing. British Journal of Clinical Pharmacology, 67(6), 676–680.
4. Johansson, T., Abuzahra, M. E., Keller, S., et al. (2016). Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis. British Journal of Clinical Pharmacology, 82(2), 532–548.

5. Santschi, V., Chiolero, A., Colosimo, A. L., et al. (2014). Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. Journal of the American Heart Association, 3(2), e000718.

6. Spinewine, A., Schmader, K. E., Barber, N., et al. (2007). Appropriate prescribing in elderly people: how well can it be measured and optimised? The Lancet, 370(9582), 173–184.

7. Pharmaceutical Society of Australia. (2020). Medicine Management in Aged Care: Summary Paper. PSA: Canberra.

8. International Pharmaceutical Federation (FIP). (2021). Clinical Pharmacy: FIP Statements of Policy. The Hague: FIP.

9. Viktil, K. K., Blix, H. S., Moger, T. A., & Reikvam, A. (2007). Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. British Journal of Clinical Pharmacology, 63(2), 187–195.

10. Kaboli, P. J., Hoth, A. B., McClimon, B. J., & Schnipper, J. L. (2006). Clinical pharmacists and inpatient medical care: a systematic review. Archives of Internal Medicine, 166(9), 955–964.